Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Stock Traders Daily
$20.00
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Gilead Sciences Inc announces topline results from three Phase3 clinical trials


Wednesday, 18 Dec 2013 08:32am EST 

Gilead Sciences Inc:Says it has announced topline results from three Phase3 clinical trials (ION-1, ION-2 and ION-3) evaluating the investigational once-daily fixed-dose combination of the nucleotide analog polymerase inhibitor sofosbuvir (SOF) and the NS5A inhibitor ledipasvir (LDV). 

Company Quote

107.58
0.07 +0.07%
29 Aug 2014